Evidence Level:Sensitive: C3 – Early Trials
Title:
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFß and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Excerpt:Responses occurred irrespective of PD-L1 expression or microsatellite instability status and appeared to correlate with high tumor TGFB1 levels…. In this first evaluation in Asian patients with heavily pretreated advanced GC/GEJC, bintrafusp alfa demonstrated a manageable safety profile and clinical activity.
DOI:10.1158/1078-0432.CCR-19-3806